In mid‑June 2026 I published my last article about Novo Nordisk A/S ( NVO ). Analyst’s Disclosure: I/we have a beneficial long position in the shares of NVO either through stock ownership, options, or other derivatives. I am not receiving compensation for it (other than from Seeking Alpha). Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.